TABLE 3.
Baseline characteristics between the study and validation cohorts.
| Characteristics | Study cohort (n = 113) | Validation cohort (n = 122) | p Value |
|---|---|---|---|
| Age, yr, mean (range) | 62.21 (33–90) | 59.64 (27–92) | 0.125 |
| Sex (male/female) | 101/12 (89%) | 96/26 (79%) | 0.033 |
| Hepatitis B (yes/no) | 84/29 (74%) | 71/51 (58%) | 0.013 |
| PS (0/1) | 81/32 (72%) | 93/29 (76%) | 0.459 |
| TBIL (μmol/L), median | 17.97 ± 12.3 | 18.08 ± 8.7 | 0.409 |
| ALB (g/L), mean ± SD | 36.54 ± 5.27 | 39.1 ± 5.05 | <0.001 |
| AST (IU/L), mean ± SD | 50.56 ± 58.05 | 76.41 ± 183.62 | 0.004 |
| ALT (IU/L), mean ± SD | 40.91 ± 34.70 | 60.67 ± 136.3 | 0.022 |
| WBC (109/L), mean ± SD | 5.52 ± 2.26 | 6.06 ± 2.43 | 0.434 |
| Hb (g/L), mean ± SD | 134.65 ± 18.66 | 132.28 ± 20.25 | 0.354 |
| BCLC stage (A/B) | 29/84 (26%) | 4/118 (3%) | <0.001 |
| HKLC stage (I/II/III) | 28/41/44 | 18/53/51 | 0.144 |
| TN, mean ± SD | 3.12 ± 2.62 | 3.32 ± 1.12 | 0.423 |
| TD, cm, mean ± SD | 7.21 ± 4.24 | 7.81 ± 4.11 | 0.279 |
| BI (yes/no) | 48/65 (36%) | 40/82 (22%) | 0.139 |
PS: physical status; TBIL: total bilirubin; ALB: albumin; AST: aspartate transaminase; ALT: alanine aminotransferase; WBC: white blood cell count; TN: tumor number; TD: tumor diameter; BI: bilobular invasion; SD: standard deviation.